Le Lézard
Classified in: Health
Subjects: POLITICS, HEALTH

REPEAT: New report exposes harmful impact of Ford government's privatization scheme on local public hospitals: Health Coalition


TORONTO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- As the Ford government counters horror stories about unprecedented emergency department wait times, burgeoning deficits, and an unrelenting staffing crisis, it is running high-rotation advertisements paid for by the public to convince Ontarians that they are doing all they can to improve our health care. A new report to be released by the Ontario Health Coalition takes aim at those claims and exposes the impact of the Ford government's drive to privatize public hospital services on local public hospitals across the province. The report, based on a year-long study looking at local hospitals across Ontario, reveals the concrete costs ? both financial costs to patients and the province and services losses to local communities-- of the transfer of resources away from our public hospitals to for-profit clinics and hospitals. The report includes information on hospitals in every region of the province.

When: Wednesday, February 21
12:15 p.m. Queen's Park Media Studio, Main Legislative Building, Toronto.
1 p.m. Brampton - Outside Brampton Civic Hospital, corner of Bramalea Rd & Bovaird Dr.
12 p.m. Cornwall - Automotive Room, Benson Centre, 800 Seventh St. W.
11 a.m. London - Tonda Room, Central Public Library, 251 Dundas St.
11 a.m. Niagara - Room 108-09, Welland Civic Square, 60 East Main St. Welland
10 a.m. Waterloo - Board Room, Waterloo Public Library, 35 Albert St.

For more information:

Ontario-wide ? Natalie Mehra (cell) 416-230-6402 [email protected]
Brampton ? Janine Herrmann-McLeod 647-237-6276 [email protected]
Cornwall ? Elaine MacDonald 613-330-3117 [email protected]
London ? Peter Bergmanis 519-860-4403 [email protected]
Niagara ? Sue Hotte 905-9322-1646 [email protected]
Waterloo ? Jim Stewart 519-588-5841 [email protected]



These press releases may also interest you

at 02:05
Locate Bio Raises £9.2 Million to Progress LDGraft Clinical Study for Anterior Lumbar Interbody Fusion
Locate Bio, a pioneering orthobiologics company, today announces the successful completion of an oversubscribed £9.2 million funding round from both new investors and existing investors, Mercia Ventures and BGF. The proceeds will fund a clinical...

at 02:05
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
Positive topline results from the DESTINY-Breast06 phase 3 trial showed that ENHERTU® (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard of...

at 01:00
Philips delivers first-quarter results in line with 2024 performance improvement plan; Resolves the Respironics personal injury and medical monitoring litigation in the US for USD 1.1 billion
April 29, 2024 First-quarter highlights Group sales amounted to EUR 4.1 billion, with comparable sales growth of 2.4%Comparable order intake -3.8%, mainly due to ChinaUSD 1.1 billion Respironics litigation settlement reached in the US...

at 00:45
4P-Pharma Announces Total Capital of ?15 Million Successfully Secured in Second Closing
4P-Pharma, a Lille-based clinical-stage startup studio focused on developing curative therapies for untreated serious diseases, announces that it has successfully secured a total capital of ?15 million in its second closing with participation from...

at 00:20
PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA
PROTEINA announced today that it has held a kickoff meeting with Professor Janghee Woo and his research team at Emory University School of Medicine in Atlanta, to begin global clinical validation of its flagship product, PPI PathFinder BCL2 Dx. PPI...

at 00:00
INTREPID Alliance Landscape of Promising Antivirals in Clinical Development Reveals Gaps in Global Defense Against Potential Future Pandemics
Building on its commitment to identify strengths and gaps in the R&D pipeline for antivirals, the INTREPID Alliance, a consortium of innovative biopharmaceutical companies dedicated to accelerating antiviral treatments to help protect the world ahead...

More news about Health...


News published on and distributed by: